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Abstract. The present study was conducted in order to 
improve gene expression efficiency of insulin-like growth 
factor-1 (IGF‑1)-transfected mesenchymal stem cells (MSCs) 
using a non-viral carrier and a simplified method of dual 
gene selection. The therapeutic efficacy of this MSC‑based 
IGF‑1/enhanced green fluorescent protein (EGFP) dual gene 
sorting system was evaluated in a rat myocardial infarction 
(MI) model. IGF‑1 and EGFP genes were expressed in MSCs 
in vitro. The purity of dual gene-expressing MSCs was 95.1% 
by fluorescence‑activated cell sorting. Transfected MSCs 
injected into rats were identified based on green fluorescence, 
with an increased signal intensity observed in rats injected 
with sorted cells, compared with unsorted cells. IGF-1 expres-
sion levels were additionally increased in the sorted group, 
and decreases in infarct size, fibrotic area and fraction of 
apoptotic cells were observed. These results demonstrated that 
IGF‑1 overexpression protects against fibrosis and apoptosis 
in the myocardium and reduces infarct size following MI. 
Additionally, the present vector sorting system may potentially 
be applied to other types of stem cell‑based gene therapy.
Introduction
Cardiovascular diseases, including myocardial infarction 
(MI), hypertensive heart disease, cardiomyopathy, atrial fibril-
lation, peripheral artery disease and venous thrombosis, are 
the leading causes of mortality worldwide (1-3). MI causes 
cardiomyocyte death, scar formation, wall thinning and 
collagen degradation via blockage of coronary arteries (3,4). 
Therapeutic strategies that repair damaged cardiac tissue and 
prevent destructive ventricular remodeling following MI are 
critical for improving patient prognosis.
MI is typically treated by balloon angiography and stents, 
bypass surgery, heart transplantation and artificial heart 
surgeries (5-7). However, myocardial salvage is incomplete 
due to restenosis in these approaches (5). Furthermore, these 
strategies are costly and heart transplantations are limited due 
to the shortage of donor organs (6,7). Stem cell‑based therapies 
have been proposed as a promising approach for the treatment 
of MI (6); a variety of cell types have been used to restore 
damaged heart tissue, including cardiomyocyte progenitor 
cells, hematopoietic stem cells, mesenchymal stem cells 
(MSCs), cardiac stem cells, embryonic stem cells, skeletal 
myoblasts, and fetal and umbilical cord blood cells (6,8). MSCs 
may be easily obtained from the patient (9), making them an 
ideal cell source for transplantation into the infarcted heart. 
Furthermore, MSCs have additional advantages, including 
ease of isolation, multilineage differentiation potential, and 
immunomodulatory and paracrine effects (7,9,10).
Despite these favorable qualities, low transplanta-
tion efficiency and cell viability associated with MSC 
transplantation (10) have prompted the modification 
of MSC‑based cell therapies, including gene delivery 
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systems (10,11). Gene delivery may be achieved through viral 
and non-viral carriers (12). The former includes retrovirus, 
lentivirus and adenovirus, which are highly efficient; however, 
may additionally cause insertional mutagenesis, immunoge-
nicity and pathogenesis (13). In contrast, non-viral carriers 
are efficient delivery systems that are safe, stable, easy to 
generate and have low immunogenicity; however, are limited 
by a relatively low transfection efficiency compared with viral 
infection (12,14,15), which is a principal barrier for clinical 
applications.
Insulin-like growth factor-1 (IGF-1), which has a structure 
similar to that of insulin (16), is secreted by the majority of 
tissues and serves an important role in cell growth, differentia-
tion and transformation (17,18). IGF‑1 has been demonstrated 
to enhance cardiomyocyte function (17); its overexpression 
was demonstrated to prevent apoptosis of myocardial cells 
attenuating ventricular dilatation and wall stress in infarcted 
hearts; whereas, IGF‑1 deficiency resulted in impaired cardiac 
remodeling and increased apoptosis in MI (17). IGF-1 admin-
istration increased the expression of angiogenic factors in MI 
animal models (19). Furthermore, IGF-1 induced the activa-
tion of resident cardiac stem cells and increased engraftment 
and survival of numerous cell types, including MSCs (20). 
IGF‑1 may be administered by injection of the recombinant 
protein; however, this method is costly and inefficient due to 
the short half-life of the protein (21). In contrast, gene transfer 
using a non-viral carrier is relatively inexpensive and has low 
cytotoxicity (21).
The aim of the present study was to use MSC‑based gene 
(IGF‑1) therapy with a fluorescence-activated cell sorting 
(FACS) system to improve the therapeutic outcome in a rat 
MI model.
Materials and methods
Animals. Sprague-Dawley rats from Orient Bio, Inc. 
(Seongnam, Korea) were handled according to the Association 
for Assessment and Accreditation of Laboratory Animal 
Care International system. Animal experiments conformed to 
the International Guide for the Care and Use of Laboratory 
Animals, and experimental procedures were examined and 
approved by the Animal Research Committee of Yonsei 
University College of Medicine (Seoul, Korea). All rats were 
allowed free access to food and water. The room was kept 
at a constant temperature (22±2˚C) and relative humidity 
(50±10%) on a 12‑h light/dark cycle. The total number of rats 
used was 56: 10 rats used for MSC isolation (weight, 100±5 g; 
male; 4 weeks of age) and 46 rats used for MI model (weight, 
270±10 g; male; 8-9 weeks of age).
Const ruct ion of  the select ion vector (pEF1/His 
C::IGF‑1::EGFP). The pEF1/His C::IGF-1::EGFP selection 
vector was constructed by inserting rat IGF‑1 and enhanced 
green fluorescent protein (EGFP) DNA into the pEF1/His C 
vector (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). In the first step, total RNA was extracted from 
rat MSCs using an RNeasy Mini kit (Qiagen GmbH, Hilden, 
Germany). The MSCs cDNA was synthesized by using 
Promega RT reagents (Promega Corporation, Madison, WI, 
USA) according to the manufacturer's protocol. Briefly, RNA 
with oligo(dt) primer and Nuclease-free water was preheated 
for 5 min at 70˚C, and immediately chilled in 4˚C for at least 
5 min. Reverse transcription reaction mix (nuclease-free 
water, ImProm-II™ 5X Reaction Buffer, MgCl2, dNTP Mix, 
Recombinant RNasin® Ribonuclease Inhibitor, ImProm‑II™ 
Reverse Transcriptase) was added to RNA and primer mix. 
This mix was annealed at 25˚C for 5 min, extended at 42˚C 
for 1 h, inactivated reverse transcriptase at 70˚C for 15 min. 
Rat IGF‑1 cDNA was amplified by polymerase chain reac-
tion (PCR) with DNA polymerase (Takara Bio, Inc., Otsu, 
Japan) using rat MSCs cDNA as a template. The forward 
and reverse primers for IGF-1 contained EcoRI and XbaI 
restriction sites, respectively (Table I). The restriction site 
for EcoRI was 5'-GAATTC-3' and the restriction site for 
XbaI was 5'-TCTAGA-3'. The PCR thermocycling condi-
tions were 95˚C for 5 min, 32 cycles of 95˚C for 1 min, 65˚C 
for 1 min 30 sec, 72˚C for 40 sec, and then a final exten-
sion step at 72˚C for 10 min. The amplified PCR product 
was purified and digested with EcoRI and XbaI restriction 
enzymes. The pEF1/His C::IGF‑1 vector was constructed by 
inserting the digested IGF-1 fragment into the pEF1/His C 
vector. Expression of IGF-1 from pEF1/His C::IGF-1 was 
confirmed in H9c2 cells (KCLB no. 21446; Korean Cell Line 
Bank, Seoul, Korea) by reverse transcription (RT)‑PCR. 
The H9c2 cells were grown in DMEM (WELGENE, Inc., 
Gyeongsan, Korea) supplemented with 10% FBS (Gibco; 
Thermo Fisher Scientific, Inc.) and 1% antibiotics (Gibco; 
Thermo Fisher Scientific, Inc.) in humidified atmosphere at 
37˚C with 5% CO2. Subcloning was performed by inserting 
EGFP DNA into the pEF1/His C::IGF-1 vector; the DNA 
was isolated from the pEGFP-C1 vector (Takara Bio, Inc.) 
by digestion with AseI and MluI restriction enzymes. A 
gap‑filling DNA precipitation step was conducted followed 
by DNA ligation (T4 ligase; New England BioLabs, Inc., 
Ipswich, MA, USA). This cloned sequence of the pEF1/His 
C::IGF‑1::EGFP vector was confirmed by digesting with 
restriction enzymes and sequencing (Cosmo Genetech Co., 
Ltd., Seoul, Korea).
MSC isolation and characterization. MSCs were isolated 
from 4‑week‑old male Sprague Dawley rats (weight, 100±5 g) 
as previously described (10). Rat bone marrow (BM)‑derived 
cells were flushed out from the femur and tibia using DMEM 
(WELGENE, Inc.) supplemented with 10% FBS (Gibco; 
Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin 
solution (Gibco; Thermo Fisher Scientific, Inc.). The medium 
was collected and centrifuged at 596 x g for 5 min at room 
temperature (RT), and cells were loaded onto a Ficoll‑Paque 
density gradient medium (GE Healthcare Life Sciences, 
Uppsala, Sweden). Following centrifugation (596 x g, 30 min, 
RT), the middle layer containing mononuclear BM cells was 
removed, washed and seeded in culture dishes at 1x106 cells 
per 100 cm2. Following incubation for 72 h in humidified 
atmosphere at 37˚C with 5% CO2, adherent cells were washed 
and fresh MSC medium was added. MSCs were identified 
using a flow cytometer (FACSVerse; BD Biosciences, Franklin 
Lakes, NJ, USA) and FACSuite software (version 1.0.6; 
BD Biosciences) based on the presence of cell surface markers. 
Resuspended single cells were labeled with antibodies against 
surface markers, including anti-cluster of differentiation 
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(CD)29‑fluorescein isothiocyanate (FITC; cat. no. 102205; 
1:50), anti‑CD54‑phycoerythrin (PE; cat. no. 202405; 1:80), 
anti‑CD90‑FITC (cat. no. 202504; 1:200), anti‑CD45‑PE (cat. 
no. 202207; 1:80), and anti‑CD49d‑FITC (cat. no. 200103; 
1:200) antibodies (BioLegend, Inc., San Diego, CA, USA) in 
ice for 1 h. MSCs labeled with antibodies were sorted by flow 
cytometry.
In vitro transfection using the non‑viral carrier dendrimer 
type bio‑reducible polymer [polyamidoamine‑arginine 
grafted bio‑reducible poly (cystaminebisacrylamide‑diami‑
nohexane (PAM‑ABP)] and pEF1/His C::IGF‑1::EGFP vector 
in MSCs. MSCs were transfected with the non-viral carrier 
PAM‑ABP (supplied by Professor Minhyung Lee) and selec-
tion vector complexes at different concentrations of pEF1/His 
C::IGF‑1::EGFP (0, 0.5, 1, 2, 4, 8 and 16 µg). Complexes of 
plasmid DNA and PAM‑ABP were mixed based on weight 
ratio (1:5) and were used to treat MSCs. At 4 h after transfec-
tion, MSCs were washed and the medium was replaced with 
fresh complete medium. Transfected MSCs were continuously 
incubated for 24 or 48 h.
RT‑PCR. Cells transfected with pEF1/His C::IGF-1::EGFP 
were harvested 24 or 48 h following transfection, and total 
RNA was extracted using an RNeasy Mini kit (Qiagen 
GmbH). cDNA was synthesized by using Promega RT reagents 
(Promega Corporation) according to manufacturer's protocol. 
Briefly, RNA with oligo(dt) primer and nuclease‑free water 
was preheated for 5 min at 70˚C and immediately chilled 
in 4˚C for at least 5 min. Reverse transcription reaction mix 
(nuclease-free water, ImProm-II™ 5X Reaction Buffer, 
MgCl2, dNTP Mix, Recombinant RNasin® Ribonuclease 
Inhibitor, ImProm‑II™ Reverse Transcriptase) was added 
to RNA and primer mix. This mix was annealed at 25˚C 
for 5 min, extended at 42˚C for 1 h with inactivated reverse 
transcriptase at 70˚C for 15 min. RT‑PCR was performed 
with an AmfiEco kit (GenDEPOT, Katy, TX, USA). Primer 
sequences targeting rat IGF‑1 and GAPDH are listed in 
Table I. The PCR cycling conditions of rat IGF‑1 were 95˚C 
for 5 min, 28 cycles of 95˚C for 1 min, 65˚C for 1 min 30 sec, 
72˚C for 40 sec, and then a final extension step at 72˚C for 
10 min. Thermocycling conditions of GAPDH were 95˚C for 
5 min, 28 cycles of 95˚C for 1 min, 60˚C for 1 min, 72˚C for 
40 sec, and then a final extension step at 72˚C for 10 min. PCR 
products were loaded in 1.2% agarose gel containing red-safe 
(iNtRON Biotechnology, Seongnam, Korea). The results were 
scanned and visualized with CoreBio i-MAX™ gel imager 
analysis system (CoreBiosystem, Seoul, Korea).
ELISA. Conditioned medium from transfected MSCs was 
collected 24 or 48 h following incubation and analyzed using 
a rat IGF-1 Quantikine ELISA kit (cat. no. MG100; R&D 
Systems, Minneapolis, MN, USA) according to the manufac-
turer's protocol. Serum‑free low‑glucose Dulbecco's modified 
Eagle's medium (WELGENE, Inc.) was used as a negative 
control. All samples were assayed in triplicate, and the optical 
density was measured at 450 nm.
Fluorescence‑activated cell sorting (FACS) analysis. FACS 
analysis was performed to isolate transfected MSCs using 
a FACSAria III flow cytometer (BD Biosciences). At 24 h 
following transfection, transfected MSCs were harvested, 
washed and resuspended in FACS buffer (2 mM EDTA, 
25 mM HEPES, and 1% FBS in 1X PBS). MSCs transfected 
with pEF1/His C::IGF‑1::EGFP were identified based on green 
fluorescence using a FITC filter (488 nm). Data were analyzed 
with FACSDiva software (version 3.1.3; BD Biosciences).
MI model, cell transplantation and histology. Experimental 
MI was induced in male Sprague Dawley rats at 8-9 weeks 
of age (weight, 270±10 g) as previously described (10). 
Rats were anesthetized by intraperitoneal injection of 
Zoletil (30 mg/kg; Virbac Corporation, Carros, France) 
and Rompun (10 mg/kg; Bayer, Leverkusen, Germany) and 
ventilated with positive pressure (180 ml/min; Harvard 
Apparatus, Holliston, MA, USA). The heart was exposed 
through a 2‑cm incision in the left lateral costal rib. The 
left anterior descending (LAD) artery was ligated with 6-0 
prolene (Ethicon, Inc., Cincinnati, OH, USA) below the left 
atrium for 1 h. Reperfusion and intramyocardial injection 
of 100 µl PBS (n=10) was performed, and control (MSCs 
without transfection; n=10), unsorted (MSC transfec-
tion‑unsorted; n=13), or sorted (MSC transfection‑sorted; 
n=13) MSCs (1x106 cells in 100 µl PBS) were delivered to 
three or four different sites in the border zone. At 2 weeks 
following transplantation, the animals were re-anesthetized 
and sacrificed for histological examination.
To analyze MSC engraftment (or localization) within the 
infarcted myocardium, the heart was perfused, fixed in 10% 
formalin solution overnight at 4˚C, embedded in Optimal 
Cutting Temperature compound (Sakura, Zoeterwoude, 
The Netherlands), frozen on dry ice and cut into trans-
verse sections (10 µm) with a cryostat that were mounted 
with mounting medium containing DAPI (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA). DAPI and EGFP fluo-
rescence was detected by confocal fluorescence microscopy 
(magnifications, x100 and x400).
Table I. Primer sequences for reverse transcription‑polymerase chain reaction.




EGFP, enhanced green fluorescent protein; IGF‑1, insulin‑like growth factor‑1.
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Immunofluorescence analysis. To confirm IGF‑1 expression in 
MSCs transfected with pEF1/His C::IGF-1::EGFP in ischemic 
hearts, frozen tissue sections were permeabilized with PBS 
containing Triton X‑100 (Sigma‑Aldrich; Merck KGaA, 
Darmstadt, Germany), quenched with 100% methanol and 
30% H2O2, washed with PBS, and blocked with 3% bovine 
serum albumin (GenDEPOT, Katy, TX, USA) at RT for 1 h. 
Cryosections were incubated with primary antibody against 
IGF‑1 (cat. no. sc‑1422, 1:50; Santa Cruz Biotechnology, Inc.) 
in blocking solution at RT for 2 h followed by Cy5.5 donkey 
anti‑goat secondary antibody (cat. no. sc‑45102, 1:200; Santa 
Cruz Biotechnology, Inc.) at RT for 1 h. The sections were 
mounted in mounting medium containing DAPI and examined 
under a fluorescence microscope (Olympus Corporation, 
Tokyo, Japan) for detection of DAPI and Cy5.5 fluorescence 
(magnification, x100).
2,3,5‑Triphenyltetrazolium chloride (TTC) staining. 
Myocardial infarct size was measured by staining with TTC 
(Sigma‑Aldrich; Merck KGaA). Hearts isolated from rats were 
incubated in 1% TTC for 15 min at 37˚C, cut into transverse 
sections, and imaged with a digital camera (Samsung Electrics 
Co., Ltd., Suwon, Korea). Infarct size was measured by calcu-
lating the ratio of the cumulative infarcted area to that of the 
entire left ventricle using ImageJ software (version 1.51j8; 
National Institutes of Health, Bethesda, MD, USA).
Masson's trichrome staining. Fibrosis in the heart following MI 
was evaluated by Masson's trichrome staining (Sigma‑Aldrich; 
Merck KGaA) according to the manufacturer's protocol. In 
brief, sections were stained with Bouin's solution at 56˚C for 
15 min, Weigert's iron hematoxylin solution for 15 min and 
Blebrich scarlet‑acid fuchsin for 5 min. The sections were 
placed in working phosphotungstic/phosphomolybdic acid 
solution for 5 min, Aniline blue solution for 5 min, and 1% 
acetic acid for 2 min. Stained sections were mounted with 
Permount (Thermo Fisher Scientific, Inc.) and scanned to 
digitalize at x200 magnification using an Aperio AT2 (Leica 
Biosystems, Wetzlar, Germany).
Termina l  deox ynucleot ide  t rans ferase‑media ted 
dUTP nick‑end labeling (TUNEL). Apoptotic cells in 
paraffin‑embedded heart tissue sections were detected with 
the TUNEL assay using a commercial kit (Merck Millipore, 
Billerica, MA, USA) according to the manufacturer's protocol. 
Briefly, the paraffin‑embedded heart tissue sections were 
pretreated with proteinase K (20 µg/ml) for 15 min, quenched 
in 3% H2O2 for 5 min at RT, and immediately equilibrated. 
The tissue sections were reacted with the TdT enzyme at 37˚C 
for 1 h, and incubated with digoxigenin conjugated nucleotide 
substrate at 37˚C for 30 min. Then, the heart sections were 
stained with 3,3‑diaminobenzene (DAB) for 5 min, coun-
terstained with hematoxylin for a short time, mounted with 
Permount (Thermo Fisher Scientific, Inc.). A total of 5 animals 
per group were analyzed. For each animal sample, apoptotic 
cells were counted in at least five different regions of the 
stained slide (magnification, x100 and x400).
Statistical analysis. Quantitative data are expressed as the 
mean ± standard deviation of 5 independent experiments. 
Differences between groups were evaluated by one‑way 
analysis of variance followed by Kruskal‑Wallis test and 
Dunn's multiple comparison post-hoc tests. P<0.05 was 
considered to indicate a statistically significant difference. 
Statistical analyses were performed using SPSS v.18.0 software 
(SPSS, Inc., Chicago, IL, USA) and PRISM v.5.01 (GraphPad 
Software, Inc., La Jolla, CA, USA).
Results
Construction of the selection vector expressing IGF‑1 and 
EGFP. The pEF1/His C::IGF-1::EGFP selection vector was 
constructed by inserting rat IGF‑1 cDNA and EGFP DNA 
into the pEF1/His C vector (Fig. 1A and B). The sequence of 
the cloned vector (pEF1/His C::IGF‑1 vector; 6,645 bp) was 
confirmed by gene sequencing (data not shown). Expression of 
IGF‑1 from pEF1/His C::IGF‑1 was confirmed in H9c2 cells 
by RT‑PCR (0‑4 µg; Fig. 1C). The EGFP gene was subse-
quently inserted into the pEF1/His C::IGF‑1 vector (Fig. 1D). 
The final size of the cloned vector pEF1/His C::IGF‑1::EGFP 
was 6,121 bp.
Characterization of BM derived MSCs (BM‑MSCs). Rat 
primary BM‑MSCs exhibited a spindle shape (data not 
shown). To characterize the MSC phenotype, BM-MSCs 
were labeled for positive and negative cell surface markers. 
Notably, BM‑MSCs were positive for MSC markers, including 
CD29 (99.8%), CD54 (96.3%) and CD90 (99.7%), and were 
negative for CD45 (0.34%) and CD49d (0.42%; Fig. 2A). The 
efficiency of MSC transfection with the non-viral carrier 
PAM‑ABP was assessed by FACS based on the percentage 
of MSCs expressing EGFP. The efficiency of transfection of 
pEF1/His C::IGF-1::EGFP and PAM-ABP in MSCs was ~20%. 
Subsequent to sorting, the efficiency was increased to 95.1% 
by EGFP selection, corresponding to a 4.8‑times increase in 
the purity of transfected MSCs (Fig. 2B and C).
Transfection efficiency of pEF1/His C::IGF‑1::EGFP in 
rat BM‑MSCs. To determine the optimal concentration of 
pEF1/His C::IGF-1::EGFP for transfection in rat BM-MSCs, 
different amounts were transfected (0‑16 µg). The intensity 
of EGFP fluorescence was concentration‑dependent and was 
maximal at 8 µg following 24 and 48 h (Fig. 3A). IGF‑1 mRNA 
expression level was additionally increased in a concentra-
tion‑dependent manner as detected by RT‑PCR, reaching a 
maximum value at 8 µg after 48 h (Fig. 3B and C). IGF‑1 
protein expression levels in conditioned culture medium from 
transfected MSCs were measured by ELISA. Conditioned 
medium from pEF1/His C::IGF-1::EGFP-transfected MSCs 
exhibited higher expression levels of IGF‑1 compared with the 
negative control (0 µg; Fig. 3D). IGF‑1 secretion was enhanced 
at concentrations ≤8 µg and began to decline at 24 and 48 h 
following transfection (Fig. 3D). Furthermore, the amount of 
IGF‑1 secreted from transfected MSCs at 48 h post‑transfec-
tion was increased compared with 24 h following transfection.
Engraf tment of pEF1/His C::IGF‑1::EGFP‑MSCs in 
ischemic hearts. The green f luorescence associated 
with pEF1/His C::IGF-1::EGFP-transfected MSCs was 
detected in rats injected with unsorted and sorted cells. 
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Transfected MSCs were more abundant in the sorted group 
compared with the unsorted group (Fig. 4A). The pEF1/His 
C::IGF-1::EGFP-transfected MSCs were localized in the 
myocardium of the ischemic left ventricle.
Detection of IGF‑1 pEF1/His C::IGF‑1::EGFP‑MSCs in 
ischemic hearts. Red fluorescence corresponding to IGF‑1 
expression was detected in the myocardial layer of unsorted 
and sorted groups (Fig. 4B). IGF‑1 expression levels were 
Figure 1. pEF1/His C::IGF‑1 and pEF1/His C::IGF‑1::EGFP selection vector maps and identification of cloned vectors. (A) pEF1/His C::IGF‑1 vector. Rat 
IGF‑1 cDNA was inserted into the pEF1/His C vector. (B) pEF1/His C::IGF-1::EGFP selection vector. The cytomegalovirus promoter and EGFP in the 
pEGFP-C1 vector were inserted into the pEF1/His C::IGF-1 vector. (C) Reverse transcription-polymerase chain reaction analysis of IGF‑1 expression levels. 
(D) Visualization of products following digestion with NdeI and EcoRI restriction enzymes by agarose gel electrophoresis. EGFP, enhanced green fluorescence 
protein; IGF, insulin-like growth factor.
Figure 2. Characterization of MSCs derived from rat bone marrow and transfection efficiency of MSCs with pEF1/His C::IGF‑1::EGFP. (A) Expression levels 
of surface markers in the isolated MSCs were measured by flow cytometry for CD29‑FITC, CD54‑PE, CD90‑FITC, CD45‑PE and CD49d‑FITC. The red 
histograms represent staining with respective surface marker antibodies and the black histograms represent staining with isotype controls. (B) Prior to FACS, 
the transfection efficiency of MSCs with pEF1/His C::IGF‑1::EGFP and the nonviral carrier PAM‑ABP was ~20% (P4). (C) Following FACS, transfected 
MSCs were collected and the purity was increased to 95.1%. Therefore, approximately all MSCs expressed a green fluorescent signal and IGF‑1. CD, cluster 
of differentiation; EGFP, enhanced green fluorescence protein; IGF, insulin‑like growth factor; MSC, mesenchymal stem cells; FACS, fluorescence‑activated 
cell sorting cell sorting; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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Figure 3. EGFP and IGF-1 expression in MSCs transfected with pEF1/His C::IGF-1::EGFP. (A) EGFP was expressed following transfection with pEF1/His 
C::IGF‑1::EGFP. Magnification, x40. A1‑G1 (24 h) and A2‑G2 (48 h), BF; H1‑N1 (24 h) and H2‑N2 (48 h), immunofluorescence. (B) IGF‑1 expression, as 
detected by reverse transcription‑polymerase chain reaction and (C) quantification of its expression levels. (D) IGF‑1 secretion as measured by ELISA. *P<0.05, 
**P<0.01, ***P<0.001. EGFP, enhanced green fluorescence protein; IGF, insulin‑like growth factor; MSCs, mesenchymal stem cells; BF, bright field.
Figure 4. Localization of MSCs transfected with pEF1/His C::IGF‑1::EGFP in ischemic hearts. (A) Green fluorescence associated with EGFP in the ischemic 
left ventricle. n=3/group. Magnification, x100 and x400. A1‑A2 (unsorted) and A3‑A5 (sorted). (B) IGF‑1 expression (red) in BM‑MSCs was observed by 
immunofluorescence labeling. n=3/group. Magnification, x100. B1‑B2 (unsorted) and B3‑B5 (sorted). DNA is stained blue in the nuclei. MSCs, mesenchymal 
stem cells; EGFP, enhanced green fluorescence protein; IGF, insulin‑like growth factor; BM, bone marrow.
MOLECULAR MEDICINE REPORTS  18:  5563-5571,  2018 5569
increased in the sorted group compared with the unsorted 
group. Therefore, the sorting system enhances the efficiency 
of gene delivery.
Myocardial repair is improved in ischemic myocardium by 
pEF1/His C::IGF‑1::EGFP transplantation. The therapeutic 
efficacy of the system was evaluated through histological 
analysis of the infarcted tissue by TTC and Masson's 
trichrome staining. Infarct size was decreased in the sorted 
group compared with the PBS and MSC groups (P<0.05; 
Fig. 5A and B). Although the infarct size in the sorted was 
half of that of the unsorted group, the difference was not 
statistically significant (Fig. 5B). Masson's trichrome staining 
demonstrated that fibrotic area of the myocardial layer was 
significantly decreased in the sorted group compared with the 
unsorted group (P<0.05; Fig. 5C and D).
Inhibitory effects of IGF‑1 on myocyte apoptosis. Analysis of 
the apoptotic cell ratio revealed that apoptosis was decreased 
in the sorted group compared with the PBS, MSC and unsorted 
groups (P<0.05, P<0.01; Fig. 5E and F).
Discussion
BM-MSC transplantation improves cardiac function, capil-
lary density and ventricular remodeling (10,22). However, low 
Figure 5. Histological analysis. (A) Infarcted hearts were stained with 2,3,5‑triphenyltetrazolium chloride and infarct size was measured. (B) Quantification 
of infarct area. n=5/group. (C) Masson's trichrome staining of fibrosis. The heart muscle was stained red and collagen was stained blue. Magnification, x200. 
(D) Quantification of fibrosis rates. n=5/group. (E) Apoptotic cells in the infarct area were detected by TUNEL (brown) and (F) apoptotic cells were quantified. 
n=5/group. Magnification, x100 and x400. *P<0.05, **P<0.01. MSCs, mesenchymal stem cells; TUNEL, terminal deoxynucleotide transferase-mediated dUTP 
nick‑end labeling; LAD, left anterior descending artery.
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viability and poor transplantation efficiency remain principal 
challenges. Even direct transplantation of stem cells into the 
infarcted heart is ineffective: Only 1-10% of cells actually 
remain in the heart (23,24). Furthermore, owing to the low 
gene transfection efficiency of non‑viral carriers, the propor-
tion of stem cells harboring the target gene is very low (11). 
The aim of the present study was to maximize the effects of 
a therapeutic gene using FACS to obtain a highly pure popu-
lation of cells transfected with this gene. FACS analysis has 
numerous advantages over other available methods. It is the 
preferred method for obtaining a pure cell population, particu-
larly of cells expressing a very low level of a particular marker 
or when separation is based on differential marker density. In 
addition, FACS is the only available technique for isolating 
cells based on internal labeling or intracellular protein expres-
sion, including a genetically modified fluorescent protein (25). 
It additionally allows the purification of individual cells based 
on size, granularity and fluorescence (25). However, the cell 
sorting method using FACS has a disadvantage of cell loss. 
For that reason, certain researchers prefer the selection of posi-
tive transfected stem cells with chemical reagents, including 
puromycin (26,27).
The pEF1/His C::IGF-1::EGFP selection vector was 
constructed using the target gene IGF‑1 and the selection 
marker EGFP through insertion of rat IGF‑1 cDNA into the 
pEF1/His C vector (pEF1/His C::IGF‑1) followed by insertion 
of EGFP and the cytomegalovirus promoter in pEGFP-C1 
into pEF1/His C::IGF-1 (pEF1/His C::IGF-1::EGFP). The 
pEF1/His C vector was used as it contains the human elon-
gation factor-1α promoter, which has high activity in stem 
cells (28). EGFP, which demonstrates higher fluorescence 
compared with GFP, was used to visualize transfected MSCs 
for cell sorting and for MSC tracking in infarcted hearts (29). 
The two genes were inserted under the control of its own 
promoter in a single vector to avoid the generation of a fusion 
protein. The regulation of rat IGF‑1 and EGFP genes by 
the two promoters was confirmed by transfecting pEF1/His 
C::IGF-1::EGFP and the non-viral vector PAM-ABP into 
BM-MSCs. PAM-ABP (weight ratio, 1:5) functions as an 
efficient gene carrier with low cytotoxicity (30,31). The same 
weight ratio for the plasmid and non-viral carrier PAM-ABP 
was applied for MSC transfection.
IGF‑1‑expressing MSCs were isolated by FACS with a 
purity of 95.1%. When these cells were injected into MI rats, 
TTC and trichrome staining revealed that infarct size and 
fibrosis were decreased compared with animals injected with 
unsorted cells, suggesting that the high expression levels of 
IGF‑1 achieved by sorting demonstrated therapeutic effects. 
Previous studies suggested that IGF‑1 is secreted by the 
majority of tissues and serves an important role in cell growth, 
differentiation and transformation (17,18). In particular, IGF-1 
in the heart has beneficial effects on cardiomyocyte function, 
including cell proliferation and survival (17). Exogenous 
administration of IGF-1 had cardioprotective effects that 
were exerted through the Akt signaling pathway (32), and it 
was demonstrated that IGF-1 improved cardiac function and 
reduced structural damage during ischemia/reperfusion (33). 
In the present study, the TUNEL assay demonstrated that IGF-1 
had an anti-apoptotic effect on cardiomyocytes, although the 
apoptosis pathway was not investigated; the effect was most 
marked in rats injected with sorted cells. The present results 
are consistent with a previous study, in which MSC survival 
and engraftment were enhanced, and cardiac dysfunction and 
myocardial apoptosis were suppressed by transplantation of 
IGF-1-treated MSCs (20).
Echocardiographic analysis in an MI animal model 
revealed that injection of IGF-1-adipose tissue-derived 
SCs improved left ventricular ejection fraction and 
cardiac contractility index (34), in addition to cardiac 
function (32,34,35). Although echocardiography was not 
performed in the present study, histological data provided 
evidence that maximizing the efficiency of gene expression 
through a sorting system may improve cardiac function in 
the infarcted heart.
In summary, it was demonstrated that MSC‑based IGF‑1 
therapy may reduce fibrosis of the myocardium along with 
infarct size and myocyte apoptosis in a rat MI model. Although 
the safety and therapeutic efficacy of pEF1/His::IGF‑1::EGFP 
selection vector requires confirmation in larger animal models 
prior to is used in clinical applications; this strategy may 
potentially be modified for other types of cell‑based therapy 
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